PHKG Business Opportunities

Detailed analysis of five commercial opportunities for Personal Health Knowledge Graph (PHKG) infrastructure. Each builds on the same core technology — curating fragmented health data into structured, ontology-backed knowledge graphs — but targets different customers and revenue streams.

See also: Stamen Health, Stamen Health Executive Summary, PHKG Business Models & Market, AIDAVA.

Overview

The PHKG architecture from AIDAVA enables five distinct business opportunities, each with different customers, timelines, and risk profiles:

Opportunity	Customer	Revenue Model	Time to Revenue	Difficulty
1. Data Intermediary	Pharma/CRO	Commission on data access	18-24 months	High (regulatory)
2. B2B Preventive Health	Employers	Per-employee subscription	12-18 months	Medium (sales)
3. Patient Group Apps	Patients (rare/chronic)	Subscription SaaS	6-12 months	Medium (adoption)
4. GP Diagnostic Overview	GP practices	Per-practice subscription	12-18 months	High (integration)
5. Pre-Consultation Triage	GP practices	Per-consultation fee	6-12 months	Medium (simplest product)

The core PHKG technology serves all five, but each requires different product packaging, go-to-market strategy, and regulatory approach.

1. Health Data Intermediary — Hospitals Sell to Clinical Trials

Concept: Hospital collects and curates patient data into PHKG. Pharma companies pay for access to curated, de-identified patient cohorts for clinical trial recruitment, real-world evidence generation, or post-market surveillance.

How It Works

1. Hospital data (structured + unstructured) is curated into PHKG using Stamen's platform
2. Patients consent to data sharing for research (GDPR-compliant, EHDS-aligned)
3. Pharma/CRO searches the PHKG for cohorts matching trial inclusion criteria
4. Hospital receives payment per patient enrolled or per dataset accessed
5. Stamen takes a commission (platform fee) on each transaction

Market Context

Existing players:

• Datavant (US, $7B valuation 2021) — data linking and de-identification for US hospitals. Dominant in US, no EU presence.
• TriNetX (US/EU, $500M+ valuation) — federated network of 300+ organizations. Grows data, connects to pharma. Focuses on trial feasibility.
• LynxCare (Belgium, ~€50-80M) — generates real-world evidence from hospital data. Connected to Belgian hospitals.
• IQVIA (US, $35B market cap) — clinical data services. The incumbent everyone competes with.

What's different about PHKG approach:

• TriNetX and IQVIA work with structured data (ICD codes, lab values). They miss unstructured clinical notes.
• AIDAVA's NLP extracts value from discharge notes, radiology reports, specialist letters — the 80% of clinical data that's currently unstructured.
• PHKG with SNOMED CT coding enables more precise cohort matching than flat ICD-code searches.

Revenue Potential

• Per-patient-enrolled fee: €500-2,000 per patient enrolled in a clinical trial through the platform
• Dataset access fee: €10,000-50,000 per curated dataset for feasibility studies
• Commission rate: 15-30% of hospital payment

Realistic year 2 revenue: €100-300K if 1-2 hospitals are connected and 1-2 pharma/CRO partnerships exist.

Challenges

• Regulatory complexity: EHDS secondary use framework isn't finalized. GDPR consent mechanisms for data intermediaries are complex. Each country has different rules.
• Hospital willingness: Hospitals are nervous about "selling patient data." Even with consent and de-identification, there's reputational risk. The framing matters: "enabling clinical trials" not "selling data."
• Chicken-and-egg: Pharma won't pay until there's data volume. Hospitals won't invest in curation until there's pharma demand. Need a lighthouse hospital + a lighthouse pharma partner simultaneously.
• De-identification: Must be provably robust. GDPR fines for re-identification are massive. This is a trust liability.

Verdict

High potential, high difficulty. The revenue per transaction is high, but the regulatory and trust barriers are significant. Best pursued as a year 2-3 opportunity after establishing the core EHDS compliance product. Start with the hospital relationship first, add the intermediary layer later.

2. B2B Preventive Health — Employee Health Programs

Concept: Employer pays for employee health screening, data is stored in a PHKG, tracked over years. Employees get personalized health insights. Employer gets healthier workforce, reduced sick days, insurance premium optimization.

How It Works

1. Employer contracts Stamen for employee health program
2. Employees get periodic health screenings (blood tests, body scans, questionnaires) — can partner with Neko Health, Nightingale Health, or local providers
3. Screening data is curated into individual PHKGs
4. AI analyzes trends over time: cholesterol trajectory, blood pressure trends, metabolic markers
5. Employee gets personalized health dashboard with recommendations
6. Employer gets anonymized aggregate workforce health reports

Market Context

Corporate wellness market: Estimated $61B globally (2024), growing 7-8% annually. Nordic corporate wellness is a mature market with strong employer mandates.

Existing players:

• Neko Health (Sweden, $2.55B) — full-body scanning, currently B2C. No PHKG or longitudinal tracking.
• Nightingale Health (Finland, public) — blood test biomarker platform. Sells to employers for health screening.
• Wellhub/Gympass (Brazil/US) — fitness/wellness platform for employees. Not health data.
• Virgin Pulse / Personify Health — enterprise wellness platforms. Generic, not data-centric.

What's different:

• Existing corporate wellness is gym memberships, mental health apps, generic health tips. Nobody does longitudinal health data tracking with a PHKG.
• The PHKG approach means data accumulates over years. An employee's 5-year health trajectory is far more valuable than a single screening.
• AI can identify early warning signs across multiple data points that no single test catches.

Revenue Potential

• Per-employee subscription: €20-50/month per employee for screening + data platform
• Employer value prop: Reduced sick days (typical ROI: €2-5 saved per €1 spent on wellness)
• Example: 500 employees × €30/month = €15,000/month = €180,000/year
• With 10 employer clients: €1.8M ARR

Challenges

• Employee privacy concerns: Employer-funded health data creates privacy tensions. Employees worry about data being used for employment decisions. Must have iron-clad data separation (employee sees their data, employer only sees anonymized aggregates).
• Not a core competency: This is a healthcare product, not a data infrastructure product. Different sales motion, different buyer (HR director, not hospital CIO). Distracts from the core EHDS play.
• Screening provider dependency: Stamen would need to partner with screening providers (Neko, Nightingale). Margins get squeezed.
• Adoption: Employee participation rates in corporate wellness programs average 20-40%. Getting 50%+ participation requires strong employer mandates.

Verdict

Good revenue potential, but a distraction from core EHDS play. Best pursued as a later product line (year 3+) or through a partnership (e.g., provide the PHKG backend for Neko Health's B2B offering). Don't build the screening/sales operation yourself — partner with someone who already has employer relationships.

3. Patient Group Data Consolidation Apps

Concept: Patients with complex or chronic conditions (rare diseases, cancer, autoimmune) have data scattered across 5-20 hospitals, labs, and specialists. The app consolidates everything into a PHKG, AI helps curate and explain it, patients can use it for second opinions.

How It Works

1. Patient downloads app, connects to hospital portals / uploads records
2. Data is ingested, structured into PHKG using SNOMED CT
3. AI generates a unified health timeline and summary
4. Patient can ask questions about their data ("What did my MRI in 2023 show about the lesion?")
5. App highlights gaps, contradictions, or things to discuss with next doctor
6. Patient can share curated PHKG with new specialists for second opinions

Market Context

Existing players:

• PicnicHealth (US, $60M+ raised) — collects records from US hospitals, provides patient access. 12 of top 20 pharma customers. But: no AI curation, no knowledge graph, US-only.
• 1upHealth (US, $40M) — FHIR-based patient data aggregation. CMS-compliant. But: no AI, no PHKG.
• Citizen Health (US) — rare disease patient data platform. Building AI infrastructure for patient data. Early stage.
• Betterpath (US) — patient record consolidation. Very early.

What's different:

• PicnicHealth collects but doesn't curate or analyze. It's a record storage service.
• PHKG approach means the data is actually structured, queryable, and AI can reason over it.
• The "talk to your data" feature (AI explaining your records) is unique. Nobody does this well today.
• Second opinion facilitation — sharing a curated PHKG with a new doctor is more valuable than sending 200 PDFs.

Revenue Potential

• B2C subscription: €10-30/month per patient
• Target population: Rare disease patients (30M in EU), cancer survivors, autoimmune patients
• Niche first: Start with ONE rare disease community (e.g., Ehlers-Danlos, ME/CFS) where patients are highly motivated and vocal
• Example: 5,000 patients × €15/month = €75,000/month = €900,000/year

Challenges

• B2C is hard in healthcare: Patients don't pay for health data tools. Adoption is driven by free value, not subscriptions. The freemium-to-paid conversion in health apps is 1-5%.
• Hospital portal integration: Getting data out of hospital EHR systems is technically and legally complex. Each hospital has different portals, different data formats, different access rules.
• Patient motivation: Most patients don't care about their data until they need a second opinion. The app needs a trigger event (new diagnosis, hospital change, specialist visit) to drive adoption.
• Data quality: Hospital records are messy. Auto-curation needs to handle missing data, contradictory notes, outdated information.

Verdict

Compelling product, hard business model. B2C health apps rarely make money from subscriptions. But: this is the fastest to prototype (can build in 3-6 months), and the community/word-of-mouth potential is high if you pick the right patient group. Best pursued as a proof-of-concept that validates the PHKG technology with real users, even if revenue is modest initially. The real value is in demonstrating the PHKG works with messy real-world data.

4. GP Diagnostic Overview — See the Whole Patient

Concept: GP has a patient in front of them. The PHKG shows the complete patient history — every hospital visit, lab result, imaging report, specialist note — structured and summarized. AI highlights relevant history for the current complaint. GP diagnoses faster, orders fewer redundant tests.

How It Works

1. Patient's data is already in PHKG (from hospital connections or patient uploads)
2. When GP opens the patient record, they see a structured timeline + AI summary
3. AI highlights: relevant past conditions, current medications, recent trends, risk factors
4. GP can ask natural language questions: "Has this patient ever had a cardiac workup?"
5. System suggests relevant tests based on history (avoiding duplicates)

Market Context

The problem is real (with sources):

• History dominates diagnosis: Hampton et al. (1975) found that history alone yields the correct diagnosis in 75-80% of cases. Replicated by Peterson et al. (1992, 76%) and Roshan & Rao (2000, 83%). This is the strongest argument for structured pre-consultation data gathering — if the GP has the history already, consultation time shifts to treatment.

• Time pressure is severe: Wilson et al. (2024, BMJ Open) found that delivering recommended care at current volumes would require >24 hours per GP per day. Median consultation needed 15.7 minutes to deliver recommended care, but scheduled at "10 minutes." This is UK data but reflects structural time pressure common to primary care systems.

• US physician time allocation: Sinsky et al. (2016) found physicians spend ~27% of their time on direct clinical face time and ~49% on EHR/desk work. US data for 4 specialties — NOT Norway-specific.

• Norwegian GP consultation time: No verified primary source found for a single average figure. Consultation length varies by practice setting, patient age, and reason for visit. Norwegian fastlege studies exist but no authoritative national average was found.

• Duplicate testing: Figures vary by setting and study. Health information exchanges reduce redundant procedures, but the "20-30%" range lacks a single authoritative source.

• Information fragmentation: Patient data is spread across DIPS, local labs, hospital discharge letters, specialist correspondence. Well-documented as a pain point but specific time-savings figures need Norwegian primary research.

Previous claims "30-50% of consultation time gathering data" and "8/12 minute breakdown" were unsourced and have been removed.

Existing players:

• DIPS (Norway) — dominant EHR in Norwegian hospitals. Has some integration, but no PHKG or AI summarization.
• Epic/Cerner (US) — large EHRs with some cross-system data viewing. Not PHKG-based.
• Cogstack (UK) — NHS clinical NLP. Extracts information from unstructured notes. Open source. Not a GP tool.
• Tandem Health (Sweden/Norway) — AI clinical documentation. Focuses on note-taking, not data overview.

What's different:

• Current EHRs show a list of encounters. PHKG shows a structured, ontology-backed patient narrative.
• SNOMED CT coding means the system understands clinical concepts, not just text matching.
• AI summarization of the full history (not just the current note) is not done by any existing GP tool.

Revenue Potential

• Per-practice subscription: €200-500/month per GP practice
• Norwegian GP market: ~5,000 GPs, ~2,500 practices
• Example: 100 practices × €300/month = €30,000/month = €360,000/year

Challenges

• Integration hell: Connecting to GP EHR systems (DIPS, Infodoc, System X) is technically brutal. Each has different APIs, different data models, different authentication. This is 6-12 months of integration work per EHR.
• Data availability: The PHKG needs data to be useful. If only hospital data is in the PHKG (not GP notes, lab results, etc.), the overview is incomplete.
• GP adoption: GPs are conservative about new tools. They've been burned by "AI will help you" products that add clicks instead of saving time. Need to be dead simple — one-click overview, not another dashboard.
• Regulatory: Clinical decision support tools face medical device regulation (MDR). If the tool "suggests" diagnoses or tests, it may need CE marking as a medical device.

Verdict

High value, high integration pain. This is the most useful product for clinicians but the hardest to build because of EHR integration. Best pursued after the PHKG infrastructure is proven and you have hospital data flowing. Consider partnering with DIPS (Norwegian EHR) rather than building integrations yourself. Year 2-3 opportunity.

5. Pre-Consultation Triage — Patient Answers Before the Visit

Concept: Before a GP consultation, the patient answers structured questions via an app. AI triages: what symptoms to focus on, what tests to pre-order, what the GP should prioritize. Saves consultation time, improves outcomes.

How It Works

1. Patient books GP appointment
2. 24-48 hours before: patient gets a questionnaire (structured questions based on reason for visit)
3. Patient answers: symptoms, duration, severity, relevant history
4. AI triages: suggests tests to pre-order (blood work, imaging), flags urgent cases
5. GP receives summary before the consultation: patient's answers + AI triage + relevant PHKG history
6. Consultation focuses on diagnosis and treatment, not data gathering

Market Context

Existing players:

Klinik Healthcare Solutions (Finland, founded 2013) — the serious incumbent. CE-marked, deployed across NHS GP practices in England. AI patient flow management that routes patients to appropriate care. Independent health-economic evaluation by York Health Economics Consortium at Priory Medical Group: enabled delivery of 18 months' appointments in one year, £300k+ capacity savings. However: Finnish entity reported €1.49M revenue and €701k loss in FY2023, revenue down 6.1%, headcount down 14.3%. UK revenue likely booked separately. This is a signal about category willingness-to-pay, not just execution.

NHS England incumbents: The UK is not a greenfield. AccuRx, eConsult, Patchs, and Anima are already widely deployed across NHS GP practices. The NHS Long Term Plan effectively mandated electronic triage forms. These represent the realistic competitive set if Stamen targets UK or follows UK-style procurement in the Nordics.

Ada Health (Germany, $100M+ raised) — AI symptom assessment with 30K+ medical concepts. B2C app, not integrated into GP workflow. Different product (patient-facing diagnosis vs. GP-assistant triage).

Babylon Health (UK, $4B peak valuation → collapsed) — AI triage + telehealth. Failed due to overpromising and regulatory issues. Warning story: don't position as "AI doctor."

Your.MD (Norway/UK) — AI symptom checker. Pivoted, limited traction.

What's different:

• Ada and Babylon are standalone symptom checkers. They compete with the GP, not assist the GP.
• Klinik and NHS incumbents do static questionnaire triage. A PHKG-backed version with LLM-based structured history-taking is a different product.
• The LLM-augmented version is genuinely new and promising. The static-questionnaire version has a 25-year history of underwhelming results (see RCT evidence below).

RCT Evidence — What Actually Works

Static questionnaire RCTs (1997-2024): mostly null or modest results.

• ESOGER trial (2024): null results on consultation length and outcomes.
• VISIT trial (2022): no satisfaction effect, slight agenda-setting increase.
• These trials tested static forms filled before appointments. The evidence is clear: static questionnaires alone don't meaningfully reduce consultation time or improve outcomes.

LLM-augmented version: genuinely promising.

• PreA RCT (Nature Medicine, January 2026, n=2,069, 111 specialists): 28.7% reduction in consultation duration using LLM-based structured history-taking. However: this was specialist care, not GP. Generalisation to primary care is uncertain.

Key insight: The defensible version of this opportunity is narrower than generic "pre-consultation triage": LLM-based structured history-taking integrated into the GP's existing EHR, positioned as assistant not replacement, with a measurable consultation-time outcome.

Revenue Potential

• Per-consultation fee: €2-5 per pre-consultation triage
• Or per-practice subscription: €100-300/month per GP practice
• Norwegian GP consultations: ~20 million/year across ~5,000 GPs
• Example: If used for 10% of consultations at €3 each = 2M consultations × €3 = €6M addressable market in Norway alone

Challenges

• Simplicity is everything: If the questionnaire takes more than 3 minutes, patients won't do it. Must be dead simple.
• GP trust: GPs will ignore AI triage suggestions if they're wrong 20% of the time. Need very high accuracy for the specific triage use case (not general diagnosis).
• Babylon warning: Babylon raised $4B and collapsed. The lesson: AI triage in healthcare is harder than it looks, and overpromising kills trust. Must underpromise and overdeliver.
• Test pre-ordering: Getting labs to accept pre-orders from an app requires integration with lab systems. Not trivial.
• Regulatory: If the tool suggests specific tests, it's clinical decision support → potentially needs MDR certification.

Verdict

The problem is real and well-evidenced, but "simplest product, fastest to revenue" is misleading. The simplicity is in the build, not in trust, adoption, regulatory clearance (MDR), or willingness-to-pay. A decade-old, CE-marked, NHS-deployed Nordic competitor (Klinik) doing ~€1.5M revenue and losing money is the relevant base rate.

The defensible version is narrower: LLM-based structured history-taking integrated into the GP's existing EHR, positioned as assistant not replacement, with a measurable consultation-time outcome. The PreA RCT (28.7% reduction) is the evidence to build on. Static questionnaires have 25 years of underwhelming RCT results — don't build that.

Regulatory risk: If the tool suggests specific tests or diagnoses, it's clinical decision support → potentially needs CE marking as a medical device (MDR). Questionnaire-only approach has lower regulatory burden but also lower value.

Babylon is a warning: Don't position as "AI doctor." Position as "structured history-taking assistant." Underpromise, overdeliver."

Recommended Sequencing

Phase	Product	Why This Order
Year 1	5. Pre-Consultation Triage	Simplest product, fastest to revenue, validates GP relationship
Year 1-2	3. Patient Group Apps	Proves PHKG with real users, builds community, generates case studies
Year 2	1. EHDS Compliance (core)	Core product — hospital data curation for EHDS. Builds the data foundation.
Year 2-3	4. GP Diagnostic Overview	Uses PHKG data from EHDS product. High value, high integration cost.
Year 3+	2. B2B Preventive Health	Partnership play. Don't build screening/sales operation.
Year 3+	1. Data Intermediary	Add layer after hospital data is flowing. High regulatory complexity.

Start with the simplest product that proves the technology and generates revenue. Build toward the core EHDS play. Add data monetization layers only after the data infrastructure is established.

See Also

• Stamen Health — strategic positioning
• Stamen Health Executive Summary — one-page plan
• AIDAVA — research foundation
• PHKG Business Models & Market — market sizing
• Companies — competitor database
• AIDAVA Competitive Analysis — detailed competitive landscape